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Introduction: Lymphoepithelioma is a very rare form of malignant tumor originating from epithelial line cells. Its
occurrence has potential clinical, therapeutic and prognostic implications. In the present report we describe an
unusual case of bladder cancer with two different histological varieties: transition cell carcinoma and
lymphoepithelioma-like carcinoma. Lymphoepithelioma-like carcinoma of the bladder has only been rarely reported
in the literature to date.
Case presentation: We present the case of a 68-year-old Caucasian man who, after occurrence of hematuria,
underwent transurethral resection of a bladder tumor. The results of a histological examination confirmed a high-grade
non-muscle-invasive pT1 lymphoepithelioma-like carcinoma of the urinary bladder, associated with a concurrent
high-grade transition cell carcinoma. After analyzing the histological features, our patient was subjected to
treatment with intra-vesical instillations of bacillus Calmette-Guérin. Our work stresses that diagnosis and
therapeutic approaches can be difficult and controversial, especially in the early stages of this rare carcinoma.
Conclusions: This report emphasizes the importance of extending our knowledge and experiences regarding this
uncommon carcinoma. Further studies are needed to better understand this rare disease and define more
accurate diagnostic and therapeutic strategies.
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Lymphoepithelioma-like carcinoma (LELC) is a rare form
of poorly differentiated or undifferentiated malignant tumor
originating from epithelial line cells, described for the first
time in the nasopharynx [1].This unusual form of carcin-
oma has subsequently been described in several tissues,
including the salivary glands, soft palate, thymus, trachea,
lung, cervix, skin, stomach, breast, and whole urinary tract
[2]. The most frequent site in which it can develop seems
to be head and neck region, while the urinary tract is an
extremely rare localization. Among LELCs arising in the
urinary tract, the bladder represents the most common
site. Since 1991 no more than 80 cases of urinary bladder* Correspondence: silverio.tomao@uniroma1.it
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reproduction in any medium, provided the orLELC have been described [2,3] and it is estimated that
this kind of carcinoma represents 0.4 to 1.3 percent of all
bladder cancers [4].
The histological features of LELC include an inflam-
matory infiltrate and conspicuous lymphoid aggregates;
furthermore, syncytia of cells and prominent nucleoli can
be observed. The number of mitoses is usually high. Re-
gardless, the pathognomonic finding is the presence of
both T and B lymphocytic infiltrate; however, other in-
flammatory cells have also been described such as eosino-
phils and plasma cells. Immunochemical test results are
also important in order to demonstrate the presence of
cytokeratins; in fact, these prove the epithelial origin of
the tumor [5]. Recognizing this rare histological form of
carcinoma is important not only for diagnosis, but also
for clinical, therapeutic and prognostic implications. The
present article describes an interesting case of bladderLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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observed: transition cell carcinoma (TCC) and LELC.
Case presentation
A 68-year-old Caucasian man presented to our facility
with a three-week history of hematuria. Our patient was
a non-smoker and had not been exposed to carcinogenic
material during his lifetime. He had no history of uro-
logical problems. On an ultrasonography scan of his abdo-
men and pelvis, a 28×13mm hyper-echoic lesion on the
right side wall projecting into the bladder was observed.
No other lesions were noted on the bladder, ureter, or
renal pelvis. A transurethral resection of bladder tumor
(TURBT) was performed, and the subsequent histological
examination revealed a predominant inflammatory infil-
trate with lymphoid aggregates and a high number of
mitoses. The histological diagnosis was high-grade non-
muscle-invasive pT1 LELC of the urinary bladder associ-
ated with a concurrent high-grade TCC (Figures 1 and 2).
Consequently, a total body computed tomography (CT)
scan was performed and the presence of distant metas-
tases or lymph node involvement was excluded. After
discussion with our patient and his family, treatment with
intra-vesical instillations of bacillus Calmette-Guérin (BCG)
strain TICEW containing 200 million colony-forming units
of BCG was carried out as prophylaxis to prevent bladder
cancer recurrences. The schedule comprised a weeklyFigure 1 Histologically, lymphoepithelioma is composed of nests, she
nuclei and prominent nucleoli, and the cytoplasm borders are poorly
consists of a conspicuous lymphoid stroma with histiocytes, neutroph
the tumor is focally admixed with typical high-grade papillary urotheinstillation for the first six weeks, followed by monthly
maintenance BCG therapy for a period of 12 months. The
immunotherapy was well tolerated by our patient. No
grade 3 toxicities were reported, and the only adverse
events were strangury and microscopic hematuria. During
instillation therapy, our patient’s urine cytology showed
some atypical cells. Therefore, cystoscopy was performed
but this did not show any remaining malignancy. A uro-
logical evaluation was obtained and another TURBT was
scheduled after performing Uro-computed tomography
(Uro-CT). At the end of the treatment, a Uro-CT scan
was carried out and the results were negative. Therefore,
our patient did not undergo a second TURBT procedure.
Despite this result, multiple bladder biopsies were per-
formed and excluded LELC recurrence. Subsequently our
patient has been included in a program of periodic follow-
up examinations. At present, he is free from disease.
Discussion
LELC is an extremely rare variant of carcinoma, first de-
scribed in the bladder by Zuckerberg et al. [4]. Since 1991
there have been only a few relatively small studies on
LELC of the urinary bladder [3,6-9]. The exact pathogen-
esis of this tumor is not well established. Epstein-Barr
virus is frequently associated with lymphoepithelioma of
the nasopharynx and other tissues (lung, stomach, thymus
and salivary gland). However, this association has not beenets and cords of undifferentiated cells with large pleomorphic
defined imparting a syncytial appearance (A,B); the background




Figure 2 High-grade non-muscle-invasive lymphoepithelioma-like carcinoma of the urinary bladder associated with a concurrent
high-grade transitional cell carcinoma. Lymphoid stroma, immunostained with CD45/pan-Leu (A), includes plasma cells, CD3-positive T
lymphocytes (B) and CD20-positive B lymphocytes, the latter diffuse (C) and in follicles (D).
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been suggested that abnormalities of p53 regulation might
be crucial in the pathogenesis of LELC of the urinary
bladder [8]. The exact origin of this carcinoma is not well
known, but the expression of common urothelial markers
suggest that it could arise from stem cells [9]. LELC of the
urinary bladder must be distinguished from lymphoma or
reactive inflammatory lesions. In our patient’s case the
differential diagnosis of bladder LELC from lymphoma
(very rare bladder carcinomas) was undertaken with the
help of immunohistochemistry test results for cytokeratin
and the lymphoid markers CD45/pan-Leu, CD3 and CD20.
Given the presence of an inflammatory background, neo-
plastic cells may be exchanged for reactive histiocytes and
the lesion may be confused with chronic cystitis. Therefore,
immunohistochemistry should also be used to exclude a
histiocytic nature and avoid a misdiagnosis of chronic
cystitis [4]. Another important issue is to distinguish
LELC associated with poorly differentiated invasive TCC
from poorly differentiated squamous cell carcinoma with
associated dense lymphoplasmacytic infiltrate [11]. Un-
commonly, LELC may be accompanied by adenocarcin-
oma and squamous cell carcinoma as well, and some
reports have described this association [11]. LELC may
also develop as a pure form or more often in combination
with other kinds of neoplasm, such as TCC. Much evi-
dence suggests that TCC generally has a worse prognosisthan LELC, while focal LELC is expected to be more
aggressive than the pure form [6,7]. It is likely these
changes in prognosis are associated with the immune
response generated by these lymphoid cells against the
tumor. Amin et al. created a classification to distinguish
among various possibilities of association. Neoplasms were
categorized according to the proportional expression of
lymphoepithelial elements in the tumor mass as pure (all
lymphoepithelial elements), predominant (more than half)
or focal (less than half ) [1]. In the present work, we
describe a rare case of predominant LELC associated
with a concurrent high-grade TCC. Our patient was
alerted by early symptoms (macroscopic hematuria and
dysuria) that several investigators have suggested are
caused promptly by the inflammatory infiltration that
characterized this carcinoma [9].
The prognosis of pT1 LELC is generally positive, but
gets progressively worse with increasing stage (pT2-4).
As a result of the low incidence of this carcinoma, no
standard approach exists. There are several alternatives,
depending on the tumor stage, which include TURBT
and intra-vescical instillations in pT1 bladder LELC, and
cystectomy with or without chemotherapy or radiother-
apy for advanced stage disease [2,6,7].
It is also known that pure/predominant LELC may re-
spond to chemotherapy and may be treated with bladder
preservation. Unfortunately, the very low incidence of
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therapeutic approaches to bladder LELC makes compari-
son among these different subtypes difficult.
Tamas et al. conducted a study on 30 cases of LELC,
at various stages and with different histology types (pure,
predominant and focal). A total of 13 of these patients
(two with pT1 tumor, four with pT2, five with pT3 and
two with pT4) underwent cystectomy, with or without
prostatectomy. A five-year follow-up demonstrated a
recurrence-free risk of about 59 percent, independent of
histological subtype (pure, predominant or focal) [2]. In
the literature, few reports underline the best treatment
in cases of LELC at the pT1 stage. This may be due to
the fact that the pT2-T3 stages seem to be the most fre-
quent presentations of LELC at diagnosis [3]. In the
Tamas et al. study, only two patients at the pT1 stage
who were TURBT treated were enrolled. These patients
were free from disease at 48 months [2].
In the treatment of LELC, different chemotherapy reg-
imens have been used but the limited number of
reported cases makes the comparison difficult. In several
studies platinum-based regimens have been seen as rea-
sonable options, especially as primary chemotherapy
[12,13], but the evidence suggests that both cystectomy
and chemotherapy are indicated only for LELC from
stage T2 onwards. Instead, for pT1 LELC authors have
suggested intra-vesical instillations with epirubicin, mi-
tomycin or BCG [14]. In our patient, pT1 stage at diag-
nosis and the presence of a concurrent high-grade TCC
component prompted us to treat the tumor with TURBT
followed by BCG instillations. Early stage LELC has only
rarely been described in the scientific literature; our pa-
tient’s case suggests that bladder-preserving therapy may
also be used to successfully treat predominant LELC.
Conclusions
In summary, our experiences with our patient as outlined
in this report underline the main problems associated with
bladder LELC. First, differential diagnosis can be difficult.
Therefore, in our opinion diagnosis should be performed
preferably by an experienced pathologist. Second, due to
the lack of information regarding the best therapy for each
stage and the lack of specific guidelines, treatment is based
mainly on the results of a few reviews and case reports. In
our patient’s case, a pT1 LELC of the urinary bladder was
treated with BCG instillations. Although the follow-up
period has not yet been completed, our patient is currently
free from disease. Other studies are necessary to better
understand this carcinoma, and to define more accurate
diagnostic and therapeutic approaches.
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